Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF NOVEMBER 27, 2013 FBO #4386
SOLICITATION NOTICE

B -- Service to create thirty (30) Epstein-Barr virus transformed cell lines from blood cells, - Package #1

Notice Date

11/25/2013
 

Notice Type

Combined Synopsis/Solicitation
 

NAICS

541380 — Testing Laboratories
 

Contracting Office

Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
 

ZIP Code

20857-0001
 

Solicitation Number

FDA_14-223-SOL-1127501
 

Archive Date

12/27/2013
 

Point of Contact

Yolanda T. Peer, Phone: 8705437479
 

E-Mail Address

yolanda.peer@fda.hhs.gov
(yolanda.peer@fda.hhs.gov)
 

Small Business Set-Aside

Total Small Business
 

Description

This Combined Synopsis/Solicitation is for Service to create thirty (30) Epstein-Barr virus transformed cell lines from blood cells, with an Option for twenty (20) additional cell lines. Document Type: Combined Synopsis/Solicitation Solicitation Number: FDA_14-223-SOL-1127501 Posted Date: November 25, 2013 Response Date: December 12, 2013 NAICS Code: 541380 Contracting Office Address FDA/OO/OFBA/OAGS/DAP National Center for Toxicological Research (NCTR) 3900 NCTR Road Jefferson, AR 72079 Description This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 "Streamlined Procedures for Evaluation and Solicitation for Commercial Items", as supplemented with additional information included on this notice. This announcement constitutes the only solicitation; offers are being requested, and a written solicitation document will not be issued. The Government intends to issue a Purchase Order in accordance with FAR Part 13.106 for the attached requirement using Simplified Acquisition Procedures. The solicitation number is FDA_14-223-SOL-1127501. This solicitation is issued as a Request for Quote (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through the Federal Acquisition Circular FAC 2005-70 effective September 30, 2013. The associated North American Industrial Classification System (NAICS) code for this procurement is 541380 - Testing Laboratories; Small Business Size standards in dollars are $12million. This combined/synopsis solicitation is a Total Small Business Set Aside. The U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) requires service to create thirty (30) Epstein-Barr virus transformed cell lines from blood cells, with an Option for twenty (20) additional cell lines. Background CBER Laboratories works on a research project to generate Deoxyribonucleic Acid (DNA reference panels for blood group genotyping assays. In order to obtain an indefinite source for the genomic DNA material to make the panels, CBER needs to create cell lines from blood cells by Epstein-Barr (EB) virus transformation. The center is requesting thirty (30) cell lines, with the option of an additional twenty (20) before the end of the Fiscal Year 14. Minimum Performance Specifications: • Task 1 i. Create 30 immortalized cell lines by EB virus transformation from peripheral blood mononuclear cells (PBMCs) isolated from CPDA (citrate-phosphate-dextrose with adenine) anticoagulated whole blood (15-30 mL) ii. Contractor shall be able to create cell lines from either freshly isolated PBMCs, or cryopreserved PBMCs iii. Provide repository sample storage service iv. The center receives the whole blood in the mornings (am), and the cells are ready for creating cell lines around noon. The Service provider must be able to physically pick up the cells in the early afternoon so that the freshly isolated blood cells (PBMCs) can be processed on the same days that the cell lines will be created. v. Shall pick up PBMCs from CBER laboratory at: 5516 Nicholson Lane FDA NLRC RM-B232 Kensington, MD 20895 • Task 2 (Option) i. Create 20 immortalized cell lines by EB virus transformation from peripheral blood mononuclear cells (PBMCs) isolated from CPDA (citrate-phosphate-dextrose with adenine) anticoagulated whole blood (15-30 mL) ii. Contractor shall be able to create cell lines from either freshly isolated PBMCs, or cryopreserved PBMCs iii. Provide repository sample storage service iv. The center receives the whole blood in the mornings (am), and the cells are ready for creating cell lines around noon. The Service provider must be able to physically pick up the cells in the early afternoon so that the freshly isolated blood cells (PBMCs) can be processed on the same days that the cell lines will be created. v. Shall pick up PBMCs from CBER laboratory at: 5516 Nicholson Lane FDA NLRC RM-B232 Kensington, MD 20895 Deliverables: Task 1: 30 Transformed cell lines (Estimated Period of Performance: (Date of Award) 1/2/2014 - 4/2/2014) Task 2: 20 Transformed cell lines (Estimated Period of Performance: 4/3/2014 - 7/3/2014) FOB Destination: Contract Type: Firm Fixed Price CLIN DESCRIPTION QUANTITY UNIT PRICE TOTAL PRICE 0001 Service to create thirty (30) 30 tiny_mce_marker____________ tiny_mce_marker__________ Epstein-Barr virus transformed cell lines from blood cells Estimated Period of Performance: (Date of Award) 1/2/2014 - 4/2/2014 *Option Year 1: Estimated Period of Performance: 4/3/2014 - 7/3/2014 OPTIONAL Service to create thirty (30) 20 tiny_mce_marker____________ tiny_mce_marker__________ Epstein-Barr virus transformed cell lines from blood cells Total Price, Base Year and Option: tiny_mce_marker______________________ GSA Contract Number (If applicable): _______________________ Delivery Address US Food and Drug Administration 5516 Nicholson Lane FDA NLRC RM-B232 Kensington, MD 20895 Clauses and Provisions: The full text of FAR and HHSAR provisions and clauses may be accessed electronically at http://acquisition.gov/far/index.html or http://www.hhs.gov/policies/hhsar. CLAUSES FAR 52.212-4 Contract Terms and Conditions-Commercial Items (Sept 2013) The following FAR 52.21-4 addenda apply: FAR 52.204-4 Printed or Copied Double-Sided on Postconsumer Fiber Content Paper (May 2011) FAR 52.204-7 System for Award Management (Jul 2013) FAR 52.217-9 Option to Extend the Term of the Contract (Mar 2000) (a) "...one (1) calendar day of contract expiration;.....at least 30 calendar days before the contract expires." (b) "...shall not exceed one (1) year... FAR 52.232-99 Providing Accelerated Payment to Small Business Subcontractors (Deviation) (AUG 2012) HHSAR 352.202-1 Definitions (JAN 2006) HHSAR 352.203-70 Anti-Lobbying (JAN 2006) HHSAR 352.222-70 Contractor Cooperation in Equal Employment Opportunity Investigations (JAN 2010) HHSAR 352.223-70 Safety and Health (JAN 2006) HHSAR 352.231-71 Pricing of Adjustments (JAN 2001) HHSAR 352.242-71 Tobacco-Free Facilities (JAN 2006) Invoice Submission INVOICES SHALL NOT BE SUBMITTED MORE FREQUENTLY THAN ONCE PER MONTH THE CONTRACTOR SHALL SUBMIT ALL INVOICES TO ALL ADDRESSES IN THE MANNER SPECIFIED BELOW: (I) ONE ORIGINAL AND ONE COPY MAILED TO THE PAYMENT OFFICE AT: FDA/OC/OA/OFO/OFS Attn: Division of Payment Services 3900 NCTR Road, HFT-324 Building 50, 6th floor, 616 Jefferson, AR 72079 Fax 870-543-7224 An electronic invoice can be emailed to the following address: nctrinvoices@fda.hhs.gov (II) ONE COPY TO THE FOLLOWING INDIVIDUAL CLEARLY MARKED "FOR INFORMATION PURPOSES ONLY/COURTESY COPY ONLY": Food and Drug Administration CBER ATTN: Michelle Salvetti 5516 Nicholson Lane Kensington, MD 20895 ***Acceptable methods of delivery include: mail, hand delivery, or email The purpose of submitting this invoice is to prompt the COR to accept/receive the items in iProcurement upon receipt of the invoice. Invoices submitted under this contract must comply with the requirements set forth in FAR clauses 52.232-25 (prompt payment) and 52.232-33 (payment by electronic funds transfer - central contractor registration) and/or other applicable far clauses specified herein. To constitute a proper invoice, the invoice must be submitted on company letterhead and include each of the following: (I) Name and Address of the Contractor; (II) Invoice Date and Invoice Number; (III) Purchase Order/Award Number; (IV) Description, Quantity, Unit of Measure, Unit Price, and extended Price Supplies Delivered or Services Performed, Including: (a) Period of Performance for which costs are claimed; (b) Itemized Travel Costs, Including Origin and Destination; (c) Any other supporting information necessary to clarify questionable expenditures; (V) Shipping Number and Date of Shipment, Including the Bill of Lading Number and Weight of Shipment if shipped on Government Bill of Lading; (VI) Terms of Any Discount For Prompt Payment Offered; (VII) Name and Address of Official to whom payment is to be sent (must be the same as that in the Purchase/Award, or in a Proper Notice of Assignment) (VIII) Name, Title and Phone Number of Person to Notify in event of Defective Invoice (IX) Taxpayer Identification Number (TIN); (X) Electronic Funds Transfer (EFT) Banking Information, Including Routing Transit Number of the Financial Institution receiving payment and the number of the account into which funds are to be deposited; (XI) Name and Telephone Number of the FDA Contracting Officer Representative (COR) or Other Program Center/Office Point of Contact, as referenced on the Purchase Order; (XII) Any other information or documentation required by the purchase order/award. (XIII) Contractor is required to attach an invoice log addendum to each invoice which shall include, at a minimum, the following information for contract administration and reconciliation purposes: (a) List of all invoices submitted to date under the subject award, including the following: (1) Invoice number, amount, & date submitted (2) Corresponding payment amount & date received (b) Total amount of all payments received to date under the subject contract or order (c) And, for definitized contracts or orders only, total estimated amounts yet to be invoiced for the current, active period of performance QUESTIONS RELATING TO INVOICES SHALL BE DIRECTED TO MS. TRACI JONES or GAYLEN WILSON AT THE FDA PAYMENT OFFICE AT (870) 543-7446 OR nctrinvoices@fda.hhs.gov POINTS OF CONTACT: Yolanda Peer can be reached at Yolanda.peer@fda.hhs.gov or by phone (870) 543-7479 QUESTIONS CONCERNING TERMS OF THIS ORDER (Other than invoice-related) SHOULD BE DIRECTED TO: Yolanda Peer (870) 543-7479 The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) Direct or negotiate any changes in the statement of work; (2) Modify or extend the period of performance; (3) Change the delivery schedule (4) Authorize reimbursement to the Contractor any costs incurred during the performance of this contract; or (5) Otherwise change any terms and conditions of this contract. The Contract Officer for this order is: XXXXX, Contracting Officer 3900 NCTR Road HFT-320 Jefferson, AR 72079 Phone: (870) 543-XXXX Email: xxxxxx@fda.gov The COR is responsible for: (1) Monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) Interpreting the statement of work and any other technical performance requirements; (3) Performing technical evaluation as required; (4) Performing technical inspections and acceptances required by this contract and; (5) Assisting in the resolution of technical problems encountered during performance. The COR for this order is: To be identified at time of award. 52.212-5 Contract Terms and Conditions Required to Implement Statues or Executive Orders-Commercial Items (Sept 2013) The following FAR 52.212-5(b) clauses apply: 52.204-10, 52.209-6, 52.219-6, 52.219-28, 52.222-3, 52.222-21, 52.222-26, 52.222-36, 52.225-13, 52.232-33, PROVISIONS The following solicitation provisions apply to this acquisition: Contract Type Commercial Item - Firm fixed price. Simplified procurement procedures will be utilized. An official authorized to bind the Offeror must sign the terms and conditions of the offer. Offerors that fail to furnish required representations and certifications, or reject the terms and conditions of the solicitation, may be excluded from consideration. 52.212-1 Instructions to Offerors-Commercial Items (Jul 2013) Addendum Paragraph (c) Period for acceptance of offers: The offeror agrees to hold the prices firm until September 30, 2014 The Defense Priorities and Allocations System (DPAS) and assigned rating are not applicable to this solicitation notice. In accordance with the Debt Collection Improvement Act of 1996, in order to be considered for an award of a Federal contract, the contractor must be registered in the System for Award Management (SAM), a free web site that encompasses the capabilities of the - Central Contractor Registry (CCR); Federal Agency Registration (Fedreg); Online Representations and Certifications Application (ORCA); Excluded Parties List System (EPLS); and the Catalog of Federal Domestic Assistance. The Contractor is responsible for the accuracy and completeness of the data within the SAM database, and for any liability resulting from the Government's reliance on inaccurate or incomplete data. To remain registered in the SAM database after the initial registration, the Contractor is required to review and update on an annual basis from the date of initial registration or subsequent updates its information in the SAM database to ensure it is current, accurate and complete. Updating information in the SAM does not alter the terms and conditions of this contract and is not a substitute for a properly executed contractual document. To access the SAM website to: https://www.sam.gov/portal/public/SAM FAR 52.212-2 Evaluation - Commercial Items (JAN 1999) The provision at FAR 52.212-2 Evaluation-Commercial Items is applicable to this solicitation. The specific evaluation criteria to be included in paragraph (1) of that provision are as follows: (i) Technical Capability (ii) Past Performance (iii) Price. Factors are listed in descending order of importance. The Government will award the purchase order to the responsible offeror whose offer conforming to the solicitation will be the most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: (i) Technical capability of the items/services offered to best meet or exceed the Government requirement (ii) Past Performance (iii) Price Non-price factors (Technical and Past Performance), when combined, are significantly more important when compared to price in determining the best value to the Government; however, price remains a significant factor. Technical capability will be determined and evaluated by review of information submitted by the offeror, which must provide sufficient technical information necessary for the Government to conclusively determine that the offered services meet the technical requirements identified above. Offerors shall specifically address the specifications stated above as well as technical specifications, descriptive material, literature, brochures and other information which demonstrates the capabilities of the offeror. Past Performance will be determined and evaluated by the identification of federal, state, local Government, or private contracts for which the offeror has, in the past three (3) years, for which the offeror has provided the same service for use in same or similar applications. Provide name, telephone number, email address, contract number, past performance point of contact and dollar amount of sale. The Government is not responsible for locating or securing any information, which is not identified in the proposal, however the Government reserves the right to obtain information for use in the evaluation from any and all sources including sources outside of the Government. Offeror's shall include the firm's DUNS number with quote. Price proposed must be detailed and represent the offeror's response to the schedule of items above. 52.212-3 Offeror Representations and Certifications-Commercial Items (AUG 2013) An offeror shall complete only paragraph (b) of this provision if the offeror has completed the annual representations and certifications electronically via http://www.acquisition.gov/. If an offeror has not completed the annual representations and certifications electronically at the ORCA website, the offeror shall complete only paragraphs (c) through (o) of this provision. A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. The offer must reference solicitation FDA_14-223-SOL-1127501. Offers are due in person, by postal mail or email to the point of contact listed below on or before December 12, 2013 by 1:00 PM, (Central Standard Time) at the Food and Drug Administration, O/OFBA/OAGS/DAP, Attn: Yolanda Peer, 3900 NCTR Road, HFT-320, Building 50 - Room 420, Jefferson, AR 72079-9502 or yolanda.peer@fda.hhs.gov. For information regarding this solicitation, please contact Yolanda Peer at yolanda.peer@fda.hhs.gov.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA_14-223-SOL-1127501/listing.html)
 

Place of Performance

Address: Food and Drug Administration, CBER Laboratory, 5516 Nicholson Lane, FDA NLRC RM-B232, Kensington, Maryland, 20895, United States

Zip Code: 20895
 

Record

SN03241009-W 20131127/131125234511-1f5eaaafb6e2908639bd1cf7a6673b22 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |